MyoVista Measurements in Patients With Atherosclerosis and CAD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-01

Study Completion Date

2020-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The MyoVista system is a novel electrocardiogram technology that provides non-invasive assessment of myocardial abnormalities by analyzing energy changes at the cellular level of the myocardium.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MyoVista wavECG Clinical Evaluation: >=60 y/o Enrichment Population

NCT05364541

Health Screening

UNKNOWN NA

A Three-phase Study That Will Compare the ECG Data Recorded Using the Test Device With the Data Recorded by a Reference Device, Evaluate the ECG Signal Quality of the Test Device Over a 10-day Simulated Use Period, and Assess the Effects of Variable ECG Electrode Placement for the Test Device

NCT07200232

Healthy Subjects

COMPLETED NA

Myovista vs NT Pro-BNP Heart Failure Referral Tool

NCT05068154

Heart Failure

UNKNOWN

MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients

NCT00305240

Myocardial Infarction Arrhythmia, Ventricular Ischemic Cardiomyopathy

COMPLETED NA

Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients

NCT04083690

Heart Failure, Systolic

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MyoVista iECG Electrocardiograph is a diagnostic device used to process electrical signals transmitted through electrocardiograph electrodes and to detect ischemia abnormalities based on electrical waveform, patient data, demographics, algorithmic sensitivity and software based informatics. The MyoVista provides the clinician with a standard ECG conventional waveform, along with an additional report derived from the proprietary informatics exclusive to the MyoVista.

The device holds a lot of promise for early intervention to properly diagnose and treat patients under risk timely and effectively. The MyoVista captures and amplifies signals from the myocardial tissue. These signals are then processed and compared to an algorithm that looks for certain changes occurring in these processed waveforms. The changes that have been identified occur much sooner than those processed by a traditional electrocardiogram (ECG). These recordings focus on early detection of myocardial abnormalities by non-linear analysis of electrical activity and physiological phenomenon. This novel assessment might be capable of detecting subclinical myocardial dysfunction in a variety of heart diseases.

The study would compare MyoVista results to subclinical measures of atherosclerosis (CAC and CT angiography) in 200 subjects at risk for coronary disease. Correlations between the MyoVista reading and the presence of calcified plaque, soft plaque, CTA stenosis, will be determined.

This study has the potential to confirm MyoVista as a reliable and sensitive marker of atherosclerosis. Findings may provide a strong indication for the value of a MyoVista test to confirm CAD in clinical practice, and for the clinical application of MyoVista in management of coronary disease and atherosclerosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease (CAD) Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MyoVista

The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female gender
* From (and inclusive of) ages of 18 to 80 years
* Body mass index (BMI) between 18 and 39.9 (kg/m2)
* Able to lie (supine) still comfortably on the back for at least 20 minutes

Exclusion Criteria

* Known history of cancer, other than non-melanoma skin cancer
* Known history of heart disease or heart rhythm abnormalities
* Known history of cardiovascular disease
* Known history of Peripheral Artery Disease (PAD)
* Known history of claudication
* History of amputation or loss of limb(s)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No